Search Results - "Hassanein, T.I"

P0859 : Genotype 1 and 4 cirrhotics: What is the SVR rate in community clinics using simeprevir and sofosbuvir? by Hefner, A.M, Suliman, I, Hassanein, R, Hill, C, Pozza, R, Couturier, T.A, Reshamwala, P.A, Hassanein, T.I

Get full text

P1268 : The correlation between depression and chronic hepatic conditions as measured by the PHQ-9 depression assessment accounting for social characteristics by Hermes, J.-M, Mann-Deibert, G, Hefner, A.M, Couturier, T.A, Hill, C, Pozza, R, Reshamwala, P.A, Hassanein, T.I

Get full text

Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients with Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir with Ribavirin (AGATE-I) by Hassanein, T.I, Asselah, T, Qaqish, R.B, Hezode, C, Mulkay, J.-P, Moreno, C, ElKhashab, M, Alqahtani, S, Yu, Y, Redman, R, Mobashery, N

Get full text

Efficacy and safety of the fixed-dose combination regimen of MK3 [MK-3682/grazoprevir/ruzasvir] with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2) by Lawitz, E, Yoshida, E.M, Buti, M, Vierling, J.M, Almasio, P.L, Bruno, S, Ruane, P.J, Hassanein, T.I, Mullhaupt, B, Pearlman, B, Jancoriene, L, Gao, W, Huang, H.-C, Shepherd, A, Tannenbaum, B, Fernsler, D, Li, J.J, Grandhi, A, Liu, H, Su, M, Dutko, F, Yeh, W.W, Plank, R, Nguyen, B.-Y.T, Wahl, J, Barr, E, Butterton, J.R

Get full text

792 CLINICAL AND PERSISTENCY OUTCOMES IN HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B PLUS RIBAVIRIN by Hassanein, T.I, Ye, X, Blumentals, W.A, Brixner, D.I

Get full text

783 ASSOCIATION OF PRETREATMENT AND ON-TREATMENT FACTORS WITH NULL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN by DiBisceglie, A.M, Hassanein, T.I, Jeffers, L.J, Hamzeh, F.M, Lindsay, K.L, Chung, R.T

Get full text

SAT-277 - Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients with Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir with Ribavirin (AGATE-I) by Hassanein, T.I., Asselah, T., Qaqish, R.B., Hezode, C., Mulkay, J.-P., Moreno, C., ElKhashab, M., Alqahtani, S., Yu, Y., Redman, R., Mobashery, N.

Get full text

THU-285 - Efficacy and safety of the fixed-dose combination regimen of MK3 [MK-3682/grazoprevir/ruzasvir] with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2) by Lawitz, E., Yoshida, E.M., Buti, M., Vierling, J.M., Almasio, P.L., Bruno, S., Ruane, P.J., Hassanein, T.I., Mullhaupt, B., Pearlman, B., Jancoriene, L., Gao, W., Huang, H.-C., Shepherd, A., Tannenbaum, B., Fernsler, D., Li, J.J., Grandhi, A., Liu, H., Su, M., Dutko, F., Yeh, W.W., Plank, R., Nguyen, B.-Y.T., Wahl, J., Barr, E., Butterton, J.R.

Get full text

Improvement of hepatic coma under albumin dialysis (MARS) treatment in associated with increase of long-chain polyunsaturated fatty acids by Stange, J., Zeh, N., Oliver, D.L., Hassanein, T.I.

Get full text

Extracorporeal liver support with albumin dialysis (MARS)-clinical trial experience from 19 centers by Stange, J., Hassanein, T.I., Mehta, R.L., Mitzner, S.R., Bartlett, R.H.

Get full text

Prevalence of impaired cognitive functioning in outpatients with chronic liver disease by Hilsabeck, R.C., Hassanein, T.I., Perry, W

Get full text